Article
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
British journal of cancer - 1 Apr 2018
Peterse Elisabeth F P, Niessen Bertine, Addie Ruben D, de Jong Yvonne, Cleven Arjen H G, Kruisselbrink Alwine B, van den Akker Brendy E W M, Molenaar Remco J, Cleton-Jansen Anne-Marie, Bovée Judith V M G
Abstract excerpt
INTRODUCTION: Chondrosarcoma is a malignant cartilage-forming bone tumour in which mutations in IDH1 and IDH2 frequently occur. Previous studies suggest an increased dependency on glutaminolysis in IDH1/2 mutant cells, which resulted in clinical trials with the drugs CB-839, metformin and chloroquine. In this study, the preclinical rationale for using these drugs as a treatment for chondrosarcoma was evaluated....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.